# Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)

Study · id `cardio:ct-nct05307237` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05307237](<https://clinicaltrials.gov/study/NCT05307237>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05307237

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 518 participants.

## Technical summary

Registry record NCT05307237. Randomized; single masking; primary purpose treatment. Start 2022-04-19 (actual); primary completion 2025-12-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 518 participants (enrolled count; ClinicalTrials.gov record NCT05307237, source copy `cardio:ctgov-nct05307237-2026-03-09`, retrieved 2026-10-26)
- Started: 2022-04-19 (actual) (ClinicalTrials.gov record NCT05307237, source copy `cardio:ctgov-nct05307237-2026-03-09`, retrieved 2026-10-26)
- Primary completion: 2025-12-17 (actual) (ClinicalTrials.gov record NCT05307237, source copy `cardio:ctgov-nct05307237-2026-03-09`, retrieved 2026-10-26)
- Completion: 2025-12-17 (actual) (ClinicalTrials.gov record NCT05307237, source copy `cardio:ctgov-nct05307237-2026-03-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05307237, source copy `cardio:ctgov-nct05307237-2026-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05307237-2026-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Continuous Glucose Monitoring for High-Risk Type 2 Diabetes in the Hospital (Cyber GEMS)
- Acronym: Cyber GEMS
- Condition: Type 2 Diabetes
- Intervention (Device): Dexcom G6 Continous Glucose Monitoring Management
- Intervention (Device): Usual Care - Blinded Continuous Glucose Monitoring Management
- Lead sponsor: Scripps Whittier Diabetes Institute
- Lead sponsor class: OTHER
- Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Scripps Whittier Diabetes Institute (`cardio:org-scripps-whittier-diabetes-institute`)
- Registry lists this organization as a collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (`cardio:niddk`)

## Provenance

Content hash: 06b265e444d1c47f4a5263deeecc31140ae8c69d2fbac1912b3a1593fe7b62b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
